Table 1.
mRNA-LNP | Immunization Details | Species | Results (Antigens) | Ref. |
---|---|---|---|---|
mRNA(FLuc)-LNP | A single intramuscular injection of 2 µg of mRNA | BALB/c mice | FLuc was detected at the injection site and liver (max concentration at 6 h) | [17] |
mRNA(FLuc)-LNP | A single intramuscular injection of 0.08, 0.4, 2.0, or 10 µg of mRNA | BALB/c mice | FLuc was detected at the injection site and liver (max concentration at 6 h) | [18] |
mRNA(Luc)-LNP | A single intramuscular injection of 5 µg of mRNA | BALB/c mice | +++ injection site + liver (3 h after administration) |
[19] |
mRNA(Luc)-LNP | A single intramuscular injection of 10 µg of mRNA | BALB/c mice | +++ injection site ++ liver + spleen (6 h after administration) |
[20] |
mRNA(FLuc)-LNP | A single intramuscular injection of 5 µg of mRNA | BALB/c mice | + injection site (max concentration at 6 h) |
[22] |
mRNA(Luc)-LNP | A single IV | C57Bl/6J mice | +++ liver ++ spleen + lungs, lymph nodes (max concentration at 6 h) |
[26] |
or SC injection | + lymph nodes (max concentration at 24 h) |
|||
mRNA-1273 | 13 individuals (first/second dose) | Humans | S1 antigen: plasma (max concentration at 5 days) Spike protein: plasma (max concentration at 14 days) |
[8] |
mRNA-1273 or BNT162b2 | Seven individuals (first/second dose) | Humans | Spike protein: ipsilateral axillary lymph nodes (max concentration at 16 days) |
[31] |
mRNA-1273 or BNT162b2 | ~300 individuals (first/second dose) | Humans | Spike protein: plasma (max concentration at 2 days) |
[31] |
BNT162b2 | Eight individuals (first/second dose) | Humans | Spike protein: plasma (max concentration at 14 days) |
[9] |
mRNA-1273 or BNT162b2 | 20 individuals (first/second dose) | Humans | Spike protein: plasma (in 50% of subjects, up to 187 days after vaccination) |
[34] |
mRNA-1273 or BNT162b2 | 22 individuals (first/second dose) | Humans | Spike protein: skin | [11] |
“+”: detectable, the number of plus signs indicates relative levels among different organs and tissues.